Peter Eckman
Cardiovascular Disease · Minneapolis, MNNPI 1639131345
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Abiomed at 47.7% of the total. 2025 is the largest year on record at $39,688, more than ten times the $2,095 reported in 2019. Among cardiovascular disease clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $416.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$39K
- Cvrx, Inc.$18K
- Abbott$9K
- Ancora Heart, Inc.$6K
- Medtronic$4K
- Edwards Lifesciences$3K
- plus $3K from 9 others
Across 38 payments — averaging $5551.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$211K
Across 1 payment — averaging $29,200 each. An ownership or investment interest held by the physician or an immediate family member.
- Nascent Surgical LLC$29K
What the payments were for
- Consulting fees$45,88657%
- Speaking & faculty fees$13,55017%
- Travel & lodging$11,06514%
- Food & beverage$10,33413%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 56 | $38,531 |
| Cvrx, Inc. | 38 | $18,195 |
| Abbott | 56 | $8,558 |
| Ancora Heart, Inc. | 8 | $5,699 |
| Medtronic(2 entities) | 11 | $4,006 |
| Edwards Lifesciences | 11 | $2,804 |
| Bayer | 1 | $2,148 |
| Daxor Corporation | 4 | $459 |
| Briohealth Solutions, Inc. | 2 | $223 |
| Endotronix, Inc. | 1 | $59 |
| Getinge USA Sales, LLC | 1 | $51 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Scpharmaceuticals Inc. | 1 | $34 |
| Boehringer Ingelheim | 1 | $18 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$17,410
- Impella$12,973
- AccuCinch$5,614
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$3,697
- Kerendia$2,148
- HeartMate 3 Left Ventricular Assist Device$1,453
- HeartMate 3 Left Ventricular Dev$1,413
- CARDIOMEMS$542
- BVA-100$424
- CardioMEMS HF System$327
- BRIOVAD$199
- HeartMate Touch$134
- Visia AF$131
How this compares
$80,835 in reported general payments places this provider in the 90th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 348 | $419,278 |
| VyndamaxTafamidis | 16 | $343,719 |
| JardianceEmpagliflozin | 221 | $223,074 |
| FarxigaDapagliflozin Propanediol | 173 | $196,061 |
| EliquisApixaban | 118 | $156,205 |
| XareltoRivaroxaban | 48 | $62,010 |
| Repatha SureclickEvolocumab | 24 | $23,885 |
| Sirolimus | 16 | $10,065 |
| Torsemide | 178 | $6,834 |
| Mycophenolate Mofetil | 61 | $6,814 |
| Metoprolol Succinate | 310 | $6,418 |
| Isosorbide Dinitrate | 34 | $5,985 |
| Bumetanide | 54 | $5,243 |
| Cyclosporine | 12 | $4,668 |
| Potassium Chloride | 122 | $3,857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $12 | $499,924134 claims |
| Boehringer IngelheimJardiance | $18 | $223,074221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 451 cardiovascular disease providers in Minnesota.
Other cardiovascular disease in Minneapolis
- Jeffrey ChambersMinneapolis$3.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Nedaa SkeikMinneapolis$453K
- Joao CavalcanteMinneapolis$384K
- Inderjit AnandMinneapolis$384K
- David HurrellMinneapolis$205K
- Yader Sandoval PichardoMinneapolis$157K
- Charles HerzogMinneapolis$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.